120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
海藻玉壶汤联合甲巯咪唑与甲巯咪唑单药治疗 Graves 病的短期疗效和安全性：一项使用倾向评分匹配的前瞻性研究
Authors Huang W, Cheng F , Liu X, Li X, Zhou S, Lin R, Zhu F, Mao X, Liu C, Xu S
Received 6 January 2026
Accepted for publication 10 April 2026
Published 21 April 2026 Volume 2026:19 593965
DOI https://doi.org/10.2147/IJGM.S593965
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Jacopo Manso
Wenbin Huang,1,2,* Fengyun Cheng,1,* Xiaoju Liu,1 Xingjia Li,1 Sicong Zhou,2 Rong Lin,3 Fenxia Zhu,4,5 Xiaodong Mao,6 Chao Liu,1,6 Shuhang Xu1
1Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, People’s Republic of China; 2Department of Thyroid Vascular Surgery, Second People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, 350003, People’s Republic of China; 3Department of Endocrinology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen Hospital Beijing University of Chinese Medicine, Xiamen, 361000, People’s Republic of China; 4Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, People’s Republic of China; 5Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, People’s Republic of China; 6Key Laboratory of TCM Syndrome and Treatment of Ying-Bing (Thyroid Disease) of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shuhang Xu, Email shuhangxu@163.com Chao Liu, Email liuchao@nfmcn.com
Objective: To investigate the efficacy and safety of the early addition of Haizao Yuhu Decoction (HYD) with methimazole (MMI) versus the monotherapy of MMI in treating Graves’ disease (GD).
Methods: This was a prospective observational study. A total of 198 patients with GD were assigned to either the HYD combined with MMI group or the MMI monotherapy group according to clinical judgment and patient preference. To minimize confounding bias, propensity score matching (PSM) was performed to balance baseline characteristics between the two groups. Primary (thyroid function, MMI dose) and secondary outcomes (general conditions, thyrotrophin receptor antibody [TRAb], thyroid size, peak systolic velocity of the superior thyroid artery [STA-PSV], the Thyroid-related Patient-Reported Outcome 39 [ThyPRO39] scores, traditional Chinese medicine [TCM] syndrome scores, and safety) were measured at 0 (V1), 4 (V2), 8 (V3) and 12 weeks of treatment (V4).
Results: Each group consisted of 54 GD patients after a 1:1 PSM. A greater decline in free thyroxine (FT4) (16.67 [7.64, 24.43] pmol/L vs 9.82 [3.49, 19.02] pmol/L, P = 0.018) and free triiodothyronine (FT3) (5.32 [3.10, 10.33] pmol/L vs 3.46 [1.16, 7.63] pmol/L, P = 0.043) was observed at V2 in the combination group than in the MMI group. The cumulative dose of MMI during the 12-week treatment was significantly lower in the combination group than in the MMI group (814.20 [600.00, 1050.00] mg vs 1007.10 [782.10, 1125.00] mg, P = 0.004). The combination group showed more pronounced reductions in the STA-PSV, TCM syndrome scores, and ThyPRO scores (P = 0.032, 0.010, and 0.044, respectively). The cumulative incidence of adverse events in the combination group was significantly lower than that in the MMI group (5.56% [3/54] vs 18.52% [10/54], P = 0.038).
Conclusion: The combination of HYD and MMI serves as an effective and safe treatment of GD, accelerating thyroid function recovery, reducing thyroid hormone levels and ATD dosage, alleviating hyperthyroid symptoms, and lowering the risk of adverse events.
Keywords: Haizao Yuhu decoction, Graves’ disease, methimazole, thyroid function, antithyroid drugs
1Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, People’s Republic of China; 2Department of Thyroid Vascular Surgery, Second People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, 350003, People’s Republic of China; 3Department of Endocrinology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen Hospital Beijing University of Chinese Medicine, Xiamen, 361000, People’s Republic of China; 4Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, People’s Republic of China; 5Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, People’s Republic of China; 6Key Laboratory of TCM Syndrome and Treatment of Ying-Bing (Thyroid Disease) of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shuhang Xu, Email shuhangxu@163.com Chao Liu, Email liuchao@nfmcn.com
Objective: To investigate the efficacy and safety of the early addition of Haizao Yuhu Decoction (HYD) with methimazole (MMI) versus the monotherapy of MMI in treating Graves’ disease (GD).
Methods: This was a prospective observational study. A total of 198 patients with GD were assigned to either the HYD combined with MMI group or the MMI monotherapy group according to clinical judgment and patient preference. To minimize confounding bias, propensity score matching (PSM) was performed to balance baseline characteristics between the two groups. Primary (thyroid function, MMI dose) and secondary outcomes (general conditions, thyrotrophin receptor antibody [TRAb], thyroid size, peak systolic velocity of the superior thyroid artery [STA-PSV], the Thyroid-related Patient-Reported Outcome 39 [ThyPRO39] scores, traditional Chinese medicine [TCM] syndrome scores, and safety) were measured at 0 (V1), 4 (V2), 8 (V3) and 12 weeks of treatment (V4).
Results: Each group consisted of 54 GD patients after a 1:1 PSM. A greater decline in free thyroxine (FT4) (16.67 [7.64, 24.43] pmol/L vs 9.82 [3.49, 19.02] pmol/L, P = 0.018) and free triiodothyronine (FT3) (5.32 [3.10, 10.33] pmol/L vs 3.46 [1.16, 7.63] pmol/L, P = 0.043) was observed at V2 in the combination group than in the MMI group. The cumulative dose of MMI during the 12-week treatment was significantly lower in the combination group than in the MMI group (814.20 [600.00, 1050.00] mg vs 1007.10 [782.10, 1125.00] mg, P = 0.004). The combination group showed more pronounced reductions in the STA-PSV, TCM syndrome scores, and ThyPRO scores (P = 0.032, 0.010, and 0.044, respectively). The cumulative incidence of adverse events in the combination group was significantly lower than that in the MMI group (5.56% [3/54] vs 18.52% [10/54], P = 0.038).
Conclusion: The combination of HYD and MMI serves as an effective and safe treatment of GD, accelerating thyroid function recovery, reducing thyroid hormone levels and ATD dosage, alleviating hyperthyroid symptoms, and lowering the risk of adverse events.
Keywords: Haizao Yuhu decoction, Graves’ disease, methimazole, thyroid function, antithyroid drugs